
D.A. Wallach
PersonHeard in 5 episodes across 2 shows since Oct 2026
D.A. Wallach is a healthcare and biotechnology venture capital investor and recording artist. He is a co-founder of Time BioVentures and Inevitable Ventures, and was the lead vocalist of the indie rock band Chester French.
Episodes
First heard
Guest appearances
Episodes per month
Public PodLume episodes featuring it, over the last year.
Show the data
| Month | Episodes |
|---|---|
| Dec 2025 | 0 |
| Jan 2026 | 0 |
| Feb 2026 | 0 |
| Mar 2026 | 0 |
| Apr 2026 | 0 |
| May 2026 | 0 |
| Jun 2026 | 0 |
| Jul 2026 | 0 |
| Aug 2026 | 0 |
| Sep 2026 | 0 |
| Oct 2026 | 1 |
| Nov 2026 | 4 |
Email alert
Email me when D.A. Wallach comes up on a podcast
One email a week at most, with the new episodes that mention D.A. Wallach. Free, no account needed, unsubscribe in one click.
What D.A. Wallach has said on podcasts
50 statements
Biotech companies are largely locked into an indication through their first human trial.
“once you've selected the indication or the disease you want to go after, you're kind of locked in at least through that first human trial.”
Open the episode · Founders Are Now Sending VCs a File Written for AIListen at 6:27
Late-stage private SPV deals should be compared with public-market investments.
“When you're looking at a $8 billion private company raising a Series C through an SPV, you should be comparing that to public. comps.”
Open the episode · Founders Are Now Sending VCs a File Written for AIListen at 49:54
Late-stage SPV deals have different valuations, outcomes, and risk-reward than early-stage venture funds.
“The dispersion of the outcomes is going to be radically different. The valuations are radically different and the risk reward is very different.”
Open the episode · Founders Are Now Sending VCs a File Written for AIListen at 50:10
Statements are attributed to the speaker as said on the episode and reflect their view at the time, not PodLume's. They are not advice.
Episodes
5 episodes featuring D.A. Wallach, newest first
- Nov 12, 2026
AI Rewrites Venture Capital’s PlaybookThis Week in StartupsNov 12, 2026Guest - Nov 6, 2026
AI’s market reckoning meets jobs, robotics and biotech’s next phaseTBPNNov 6, 2026Guest - Nov 6, 2026
Data-center backlash points toward a political compromiseThis Week in StartupsNov 6, 2026 - Nov 5, 2026
Split government tests markets’ appetite for uncertaintyThis Week in StartupsNov 5, 2026Guest - Oct 29, 2026
Anthropic’s S-1 tests the economics of AI’s capital raceThis Week in StartupsOct 29, 2026Guest